| Some examples of our R&D in the press | |
|---|---|
|
11 May 2012 The Economist covered the topic of antibiotic resistance and the importance of pharmas researching further ways to combat this. AstraZeneca was highlighted as one of the few drug companies still pioneering in this area and included a quote from Martin Mackay, R&D President. |
|
|
07 May 2012 Steve Yang, VP, head of R&D for Asia and emerging markets spoke to Life Science Leader Magazine about the importance of collaborations in Asia and what it means for innovation in pahrma. |
|
|
08 April 2012 The New England Cable News interviewed AstraZeneca’s John Reynders, Vice President of R&D Information, as part of their ‘This Week in Business’ programme. John talked about the future of personalised medicine, why Boston is such a ‘hotbed’ for the biopharmaceutical industry and how the upcoming BIO Convention will create opportunities for AstraZeneca. |
|
|
03 April 2012 Reuters have covered the recent collaboration between AstraZeneca and Amgen to jointly develop and commercialise five biotech drugs. |
|
|
29 March 2012 The Hindu Business Line has picked up on AstraZeneca’s multi-resistant TB research currently taking place in Bangalore, India. The article includes quotes from Dr Steve Yang, Vice-President, head, R&D, Asia & Emerging Markets. |
|
|
08 March 2012 AstraZeneca were referred to in a Reuters article about superbugs as one of the few companies still heavily involved in the R&D of antibiotics. |
|
|
23 February 2012 With the growing cost of innovation, Pharmaceutical Executive looks at the need for medicines to provide evidence of value and how AstraZeneca has taken a “step forward” in doing this. |
|
|
10 February 2012 As a new hospital superbug breaks out in Greece, John Rex, Vice President for Clinical Infection talks about a new generation of antibiotics that are currently being developed by AZ. |
|
|
Tuesday, 7 February 2012 Anders Ekblom talks to Nature about ”predictive innovation” and his new role as Head of AstraZeneca’s Science and Technology Integration Office. |
|
|
1 February 2012 AZ infection scientist published in Nature Reviews Drug Discovery on economic incentives to create new antibiotics. |
|
|
12 January 2012 AstraZeneca’s President of R&D and Microbiology Director spoke with The Telegraph about multi-drug resistant bacteria or “Superbugs” and the grueling battle to outsmart them in the search for new antibiotics. The Telegraph |
|
|
17 October 2011 In an Alzheimer Research Forum article, Kevin McKenna, Vice President for Regulatory Affairs in the Neuroscience Therapeutic Area, weighed in on a decision by the European Medicines Agency to incorporate a new method of selecting Alzheimer’s patients for clinical trials. Alzheimer Resarch Forum |
|
|
14 October 2011 Vice President and Head of Systems Development and R&D Information Sean Murphy spoke with the Boston Business Journal about finding qualified candidates for IT positions. Boston Business Journal |
|
|
12 October 2011 Bob Holland, Vice President for Personalised Healthcare and Biomarker Support, was interviewed by Scrip World Pharmaceutical News regarding AstraZeneca’s investment in personalised medicine. Holland was also featured in an EP Vantage article about AstraZeneca’s role in the continued growth of the field. Scrip World Pharmaceutical News EP Vantage |
|
|
10 October 2011 AstraZeneca was featured in a Reuters article about the company’s $200 million investment in a new medicines factory in China. Reuters |
|
|
7 September 2011 Fierce Biotech take a look at AstraZeneca’s expanded operations and R&D efforts in the Boston area. Fierce Biotech |
|
|
6 September 2011 Martin Mackay, AstraZeneca’s president of Research and Development, spoke to the Boston Globe on the company’s growing presence in the Boston area. Boston Global |
|
|
August 2011 Nature Reviews recently spoke with Mene Pangalos, Executive Vice President of Innovative Medicines at AstraZeneca, on partnerships with academia. Nature reviews |
|
|
12 July 2011 AstraZeneca included in Economist Intelligence Unit report, "The innovation imperative in biopharma". Economist Intelligence Unit |
|
|
June 2011 Martin Mackay PhD, President R&D, was interviewed by IN VIVO’s Melanie Senior for an exclusive feature written about AZ for the June issue of the print publication. Gunnar Olsson, Clive Morris and Bahija Jallal have also been quoted. IN VIVO publication - AstraZeneca rebuilds R&D amid growing near-term pressures (PDF 671kb) |
|
|
28 June 2011 Jit Patel, head of AstraZeneca's neuroscience preclinical business development, was quoted in a Fierce Biotech story about partnerships between pharmaceutical companies and academic institutions. The piece, by Maureen Martino, was part a recap of events from day one at BIO. Fierce Biotech: Live from BIO 2011 |
|
|
31 May 2011 PharmaVoice recently interviewed Cecilia Schott, Business Development Director in AstraZeneca's Personalized Healthcare group. PharmaVoice |
|
|
9 May 2011 Anastasia Christianson, Senior Director and Global Discipline Lead for Biomedical Informatics for Clinical Development at AstraZeneca , spoke with Chemical Engineering News on new challenges in data analysis. Chemical Engineering News |
|
|
5 May 2011 China Bio Today spoke with Steve Yang, Vice-President and Head of R&D for Asia, on business and research practices in the region. ChinaBio Today |
|
|
7 April 2011 Dr. John Rex, Vice President, Clinical Infection at AstraZeneca, spoke with editors at Scientific American on combating drug resistance. Dr. John Rex also spoke with World Radio Switzerland on drug resistant bacteria. Scientific American World Radio Switzerland |
|
|
2 March 2011 AstraZeneca’s participation in the MM4TB consortium which aims to develop drugs to combat TB, which kills 1.8 million people a year. The Guardian |
|